Methods for determining treatments for cancer patients are disclosed.

A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan v integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.

The present invention pertains to a method for identifying anti-cancer compounds. The invention is based on the finding that a direct protein-protein interaction between 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4) and (F-box protein 28) FBXO28 silences a ubiquitin E3 ligase activity of FBXO28 towards HIF1a. Interfering with this protein-protein interaction leads to a strong induction of HIF1a proteasomal degradation and cell death in tumors, and therefore, compounds screened according to the present invention harbour therapeutic potential for the treatment of proliferative diseases such as cancer. The invention provides a screening method for cancer therapeutics based on the interaction of PFKFB4 and FBXO28, as well medical applications thereof.

The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.

Disclosed are surprising new methods and kits for identifying and treating patients treatable with PS-targeting antibodies, particularly for identifying and treating cancer patients using bavituximab and bavituximab combination therapies. The methods and kits are based on the surprising finding that defined ranges of pre-treatment blood concentrations of 2-glycoprotein 1 (2GPI), particularly functional 2GPI, act as an indicator to accurately predict patients with better treatment outcomes.

Disclosed herein is a soluble protein signature from the tumor microenvironment that can predict overall survival post-surgery in pancreatic adenocarcinoma. The disclosed protein signatures provide a precision approach to surgical therapy for patients with pancreatic cancer. Also disclosed herein is a soluble protein signature from the tumor microenvironment that can diagnose pancreatic ductal adenocarcinoma (PDAC). Also disclosed herein are proteins that can be used to accurately normalize protein levels in a pancreatic sample.

The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

This invention relates to methods of characterising mammalian cells, e.g. mammalian cancer cells, based on their chemotypic signature. The methods comprise contacting test mammalian cells with a panel of reference compounds, measuring the effect of each reference compound on a phenotypic property of the test mammalian cells to produce a score for each reference compound in the panel, combining the scores to produce a chemotypic signature, and comparing this signature to the signatures of a set of reference mammalian cell lines. This may be useful for diagnostic and prognostic applications, as well as rational drug design, patient stratification, and personalised drug discovery.

The use of mitochondrial protease OMA1 as a theranostic marker for breast cancer, tumor progression, metastatis and drug responsiveness is disclosed herein.

An anti-cancer agent is provided comprising a tumour homing peptide having, or having been modified to present, two cysteine residues, with an arsenic atom between, such that the tumour homing peptide cyclises to give an arsenic-containing anti-cancer agent. This allows for selection of an appropriate tumour homing peptide for treatment of a given cancer whereby the subsequent agent provides for a more targeted delivery of arsenic to the tumour microenvironment.